Medscape has reported the results of its 2020 annual physician survey, This year rheumatologists (60%), general surgeons (60%), public health and preventive medicine physicians, and allergists/immunologists are the "happiest" outside of work compared to other specialists, according to Medscape.
Lowest in happiness were internal medicine, critical care and neurology (44-48%).
Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.
Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. The podcast covers: best therapies for dactylitis and enthesitis; we have a new knockout for knee pain in OA; and are you on the naughty or nice list when it comes to the new ACR-AF guidelines for arthritis? This and more. Tune in.
A group of Western Australian clinicians have set out to assess current practices and proved guidance recommendations for high-quality care for the most common musculoskeletal (MSK) pain scenarios encountered by clinicians in emergency and primary care. They have promulgated 11 high-quality clinical practice guidelines (CPGs).
A study from the Journal of Vascular and Interventional Radiology has shown that knee pain secondary to osteoarthritis (OA) may be effectively treated by selective vascular interruption (embolization) showing efficacy and safety in a small pilot trial.
2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology. Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond.
Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee. The ACR periodically updates guidelines to reflect any advances in management added to the literature since the last publication, which in this case was 2012.
Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.
Dr. Jack Cush reviews highlights from 2019 on RheumNow.com. Topics covered in this annual review include: superheroes lost; venous thromboembolic events and JAKs; free medical tuition; women in rheumatology; 52 new drug approvals in 2019 and 330 drugs with a 2020 price hike; scleroderma disappointments; novel new treatments and newer tests; the boom of Shingrix; RheumNow.Live - and more.
Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.